drugset / Trial / NCT00546143
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
Timeline
- Start
- 2007-07
- Primary completion
- 2008-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 450 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 525 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 600 mg | Subcutaneous |